BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-256@pharmaconomics
DTSTAMP:20260707T034239Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:ACLX PDUFA — anito-cel
DESCRIPTION:The FDA's approval decision on anito-cel for relapsed or refractory multiple myeloma is due Dec 23\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937dex991.htm\n\nTrack it: https://www.pharmaconomics.com/e/256
URL:https://www.pharmaconomics.com/e/256
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ACLX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR